The company states: "Acorda Therapeutics announced that the Nasdaq Hearings Panel has granted the Company’s extension request until June 20, 2023 to regain compliance with the Nasdaq’s minimum $1 bid price per share requirement. If at any time before June 20, 2023 the bid price of Acorda’s stock closes at or above $1 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the Nasdaq Listing Rules. In the event that the Company cannot regain compliance organically during the extension period, the Company has committed to effecting a reverse stock split, which was authorized by shareholders in November 2022."
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ACOR:
- Acorda Therapeutics enters new long-term supply pact with Catalent on INBRIJA
- Acorda Therapeutics Sees FY23 Ampyra Sales $74.6M – $82.4M
- Acorda Therapeutics sees FY23 revenue $122.2M – $135M
- Acorda Therapeutics receives non-compliance letter from NASDAQ
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue